Browsing Modes for Business Users

CD52 antibody | YTH34.5

ISO 9001 Quality Assurance Manufacturing | Print
Anti Human CD52 Antibody, clone YTH34.5 thumbnail image 1 Anti Human CD52 Antibody, clone YTH34.5 thumbnail image 2 Anti Human CD52 Antibody, clone YTH34.5 thumbnail image 3 Anti Human CD52 Antibody, clone YTH34.5 thumbnail image 4 Anti Human CD52 Antibody, clone YTH34.5 thumbnail image 5
Anti Human CD52 Antibody, clone YTH34.5 gallery image 1
Figure A. Alexa Fluor 488 conjugated Mouse anti Human CD3 (MCA463A488) and Amethyst Orange conjugated Rat IgG2b isotype control (MCA6006AMO). Figure B. Alexa Fluor 488 conjugated Mouse anti Human CD3 (MCA463A700) and Amethyst Orange conjugated Rat anti Human CD52 (MCA1642AMO). All experiments performed on human blood gated on live single lymphocytes, in the presence of 10% human serum. Data acquired on the ZE5 Cell Analyzer
Anti Human CD52 Antibody, clone YTH34.5 gallery image 2
Figure A. Pacific Blue conjugated mouse anti human CD3 (MCA463PB) and RPE conjugated rat IgG2b isotype control (MCA6006PE). Figure B. Pacific Blue conjugated Mouse anti Human CD3 (MCA463PB) and RPE conjugated mouse anti human CD52 (MCA1642PE). All experiments performed on red cell lysed human blood gated on lymphocytes in the presence of 10% human serum. Data acquired on the ZE5 Cell Analyzer.
Anti Human CD52 Antibody, clone YTH34.5 gallery image 3
Published customer image:
Rat anti Human CD52 antibody, clone YTH34.5 (MCA1642) used for staining lymphoma tissue specimens by immunohistochemistry on formalin fixed, paraffin embedded sections.
Image caption:
Positive CD52 IHC from representative DHL cases reveals a range of staining intensities: 1+ (A), 2+ (B), and 3+ (C). H&E stain of the strongly CD52-positive DHL case depicted in C (D). Many cases exhibited uniform staining intensity (E), while others showed variable CD52 expression (F).

From: Craig JW, Mina MJ, Crombie JL, LaCasce AS, Weinstock DM, Pinkus GS, et al. (2018)
Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility.
PLoS ONE 13(7): e0199708.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Anti Human CD52 Antibody, clone YTH34.5 gallery image 4
Published customer image:
FITC conjugated Mouse anti Human CD52 antibody, clone YTH34.5 (MCA1642F) used for the evaluation of CD52 expression on human cell lines by flow cytometry.
Image caption:
WM-specific antigen expression compared across RPCI-WM1, BCWM.1 and MWCL-1 cell lines.
Fluorescein (FITC), phycoerythrin (PE), phycoerythrin—cyanine 5 (PC5) or allophycocyanin (APC) conjugates of various antibodies were used as presented above. All cell lines were negative for CD10 and 11c. Blue line indicates RPCI-WM1 antigen expression, red line indicates MWCL-1 antigen expression and green line indicates antigen expression in BCWM.1 cell line. Only BCWM.1 an MWCL-1 were CD19+, CD20+ and FMC7+. Expression of CD138 and κ-light-chain was seen only on MWCL-1 and RPCI-WM1 cells. CD28 expression was markedly more observable on RPCI-WM1 tumor cells as compared to MWCL-1 or BCWM.1.

From: Paulus A, Chitta KS, Wallace PK, Advani PP, Akhtar S, Kuranz-Blake M, et al. (2015)
Immunophenotyping of Waldenströms Macroglobulinemia Cell Lines Reveals Distinct Patterns of Surface Antigen Expression: Potential Biological and Therapeutic Implications.
PLoS ONE 10(4): e0122338.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Anti Human CD52 Antibody, clone YTH34.5 gallery image 5
Published customer image:
FITC conjugated Mouse anti Human CD52 antibody, clone YTH34.5 (MCA1642F) used for the evaluation of CD52 expression on RPCI-WM1 cells by flow cytometry.
Image caption:
Expression of WM-specific antigens present on RPCI-WM1.
For antigen detection, fluorescein (FITC), phycoerythrin (PE), phycoerythrin—cyanine 5 (PC5) or allophycocyanin (APC) conjugates of various antigen-specific antibodies were used. Flow cytometry shows the RPCI-WM1 cell line to be CD10, 11c, 19, 20, 23, 27, 40, 52 and 79b negative and CD22, 28, 38, 45, 45RO, 38, 138, κ light chain and intracellular-κ positive.

From: Paulus A, Chitta KS, Wallace PK, Advani PP, Akhtar S, Kuranz-Blake M, et al. (2015)
Immunophenotyping of Waldenströms Macroglobulinemia Cell Lines Reveals Distinct Patterns of Surface Antigen Expression: Potential Biological and Therapeutic Implications.
PLoS ONE 10(4): e0122338.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.

Rat anti Human CD52:RPE

Product Type
Monoclonal Antibody
Clone
YTH34.5
Isotype
IgG2b
Specificity
CD52

Quick Links:

 Antibody Quality and Performance Guarantee
 Unrivaled Technical Support
Product Code Applications Pack Size List Price Your Price Qty
MCA1642PE
Datasheet Datasheet Datasheet
SDS Safety Datasheet SDS
F 100 Tests loader
List Price Your Price
loader
MCA1642PET
Datasheet Datasheet Datasheet
SDS Safety Datasheet SDS
F 25 Tests/0.25ml loader
List Price Your Price
loader

Rat anti Human CD52 antibody, clone YTH34.5 recognizes the human CD52 antigen, also known as CAMPATH-1. The CD52 antigen is a remarkably small but heavily glycosylated peptide attached to the cell surface membrane via a GPI link (Xia et al. 1991).

The apparent molecular mass of the native antigen on SDS-PAGE is 25-29 kDa, considerably reduced following N-glycanase treatment (Rowan et al. 1998).

CD52 is expressed at high density by lymphocytes, monocytes, eosinophils, thymocytes and macrophages. It is expressed by most lymphoid derived malignancies, although expression on myeloma cells is variable.

Humanized versions of CAMPATH-1 specific antibodies are currently in clinical trials for the treatment of a range of lymphoid malignancies (Dearden et al. 2002; Pettitt et al. 2012).

Target Species
Human
Species Cross-Reactivity
Target SpeciesCross Reactivity
Rhesus Monkey
N.B. Antibody reactivity and working conditions may vary between species.
Product Form
Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized
Reconstitution
MCA1642PE: Reconstitute with 1 ml distilled water
MCA1642PET: Reconstitute with 0.25ml distilled water
Preparation
Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.09% sodium azide (NaN3)
1% bovine serum albumin
5% sucrose
Immunogen
Human lymphocytes
Max Ex/Em
Fluorophore Excitation Max (nm) Emission Max (nm)
RPE 488nm laser 496 578
Regulatory
For research purposes only
Guarantee
12 months from date of despatch

Pack Size: 100 Tests
Prior to reconstitution store at +4°C. Following reconstitution store at +4°C.
DO NOT FREEZE.
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.
Pack Size: 25 Tests/0.25ml
Prior to reconstitution store at +4°C.
After reconstitution store at +4°C.
DO NOT FREEZE.
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Flow Cytometry Neat 1/2 Pack Size: 100 Tests
Neat Pack Size: 25 Tests/0.25ml
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Flow Cytometry
Use 10μl of the suggested working dilution to label 1 x 106 cells in 100μl

How to Use the Spectraviewer

Watch the Tool Tutorial Video ▸
  • Start by selecting the application you are interested in, with the option to select an instrument from the drop down menu or create a customized instrument
  • Select the fluorophores or fluorescent proteins you want to include in your panel to check compatibility
  • Select the lasers and filters you wish to include
  • Select combined or multi-laser view to visualize the spectra

Description Product Code Applications Pack Size List Price Your Price Quantity
Rat IgG2b Negative Control:RPE MCA6006PE F 100 Tests
>
List Price Your Price
Description Rat IgG2b Negative Control:RPE

Description Product Code Applications Pack Size List Price Your Price Quantity
Human Seroblock BUF070A F 50 Test
List Price Your Price
Description Human Seroblock
Human Seroblock BUF070B F 200 Test
List Price Your Price
Description Human Seroblock

References for CD52 antibody

  1. Klangsinsirikul, P. et al. (2002) Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution.
    Blood. 99: 2586-91.
  2. Ratzinger, G. et al. (2003) Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.
    Blood. 101: 1422-9.
  3. Zand, M.S. et al. (2005) A renewable source of donor cells for repetitive monitoring of T- and B-cell alloreactivity.
    Am J Transplant. 5: 76-86.
  4. Westermann, J. et al. (2005) CD52 is not a promising immunotherapy target for most patients with multiple myeloma.
    Int J Hematol. 82 (3): 248-50.
  5. Gopcsa, L. et al. (2005) Extensive flow cytometric characterization of plasmacytoid dendritic cell leukemia cells.
    Eur J Haematol. 75: 346-51.
  6. Rodig SJ et al. (2006) Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
    Clin Cancer Res. 12 (23): 7174-9.
  7. Golay, J. et al. (2006) The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis.
    Haematologica. 91: 322-30.
  8. Miles, R.R. et al. (2007) Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report.
    Br J Haematol. 138: 506-12.
    9. View The Latest Product References
  9. Chang, S.T. et al. (2007) CD52 expression in non-mycotic T- and NK/T-cell lymphomas.
    Leuk Lymphoma. 48: 117-21.
  10. Piccaluga, P.P. et al. (2007) Expression of CD52 in peripheral T-cell lymphoma.
    Haematologica. 92: 566-7.
  11. Reimer, P. et al. (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study.
    J Clin Oncol. 27: 106-13.
  12. Hu, Y. et al. (2009) Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
    Immunology. 128: 260-70.
  13. Rizzo, K. et al. (2009) Novel CD19 expression in a peripheral T cell lymphoma: A flow cytometry case report with morphologic correlation.
    Cytometry B Clin Cytom. 76: 142-9.
  14. Haniffa, M. et al. (2009) Differential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation.
    J Exp Med. 206: 371-85.
  15. Bisig, B. et al. (2013) CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features.
    Haematologica. 98 (8): 1250-8.
  16. Paulus, A. et al. (2015) Immunophenotyping of Waldenströms macroglobulinemia cell lines reveals distinct patterns of surface antigen expression: potential biological and therapeutic implications.
    PLoS One. 10 (4): e0122338.
  17. Hotta, R. et al. (2016) CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.
    PLoS One. 11 (8): e0161618.
  18. Buckstein, R. et al. (2016) Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study.
    Clin Lymphoma Myeloma Leuk. 16 (1): 18-28.e4.
  19. Craig, J.W. et al. (2018) Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility.
    PLoS One. 13 (7): e0199708.
  20. Suwandi, J.S. et al. (2020) Multidimensional analyses of proinsulin peptide-specific regulatory T cells induced by tolerogenic dendritic cells.
    J Autoimmun. 107: 102361.

Further Reading

  1. Salisbury JR et al. (1994) Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.
    J Clin Pathol. 47 (4): 313-7.
  2. Hale G et al. (1998) Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.
    Blood. 92 (12): 4581-90.

Flow Cytometry

Immunohistology - Paraffin

Synonyms
CAMPATH-1
RRID
AB_321472
UniProt
P31358
Entrez Gene
CD52
GO Terms
GO:0005887 integral to plasma membrane
GO:0005624 membrane fraction
GO:0007204 elevation of cytosolic calcium ion concentration
GO:0031225 anchored to membrane
GO:0045730 respiratory burst

MCA1642PE

151542 1601

MCA1642PET

151543

If you cannot find the batch/lot you are looking for please contact our technical support team for assistance.

View more products with CD52 specificity

Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"

View all Anti-Human Products
Please note